<!DOCTYPE html><html lang="en"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1.0"><title>Oral Medications — SugarWise</title><link rel="stylesheet" href="styles.css"></head><body>
<nav class="navbar"><div class="navbar-inner"><a class="brand" href="index.html">SugarWise</a><a class="home-link" href="index.html">All Topics</a></div></nav>
<div class="container">
<div class="page-header"><h1>Oral &amp; Non-Insulin Injectable Medications</h1><p>Drug classes, mechanisms, dosing, side effects, and evidence-based prescribing for Type 2 diabetes</p></div>
<div class="last-reviewed">Content last reviewed: January 2026 | AI-assisted content</div>

<div class="danger"><strong>CRITICAL SAFETY NOTICE:</strong> Never start, stop, or change any medication or dosage without consulting your doctor. The drug information below is for educational awareness only. Individual dosing depends on your specific condition, kidney function, other medications, and medical history. Self-medication can be life-threatening.</div>

<div class="illus">
<svg width="280" height="100" viewBox="0 0 280 100" xmlns="http://www.w3.org/2000/svg">
<!-- Pill 1 -->
<rect x="30" y="35" width="50" height="24" rx="12" fill="#1a7a5a" opacity="0.85">
  <animate attributeName="y" values="35;30;35" dur="3s" repeatCount="indefinite"/>
</rect>
<rect x="55" y="35" width="25" height="24" rx="0 12 12 0" fill="#145e45" opacity="0.85">
  <animate attributeName="y" values="35;30;35" dur="3s" repeatCount="indefinite"/>
</rect>
<!-- Pill 2 -->
<rect x="115" y="35" width="50" height="24" rx="12" fill="#3182ce" opacity="0.85">
  <animate attributeName="y" values="35;28;35" dur="2.5s" repeatCount="indefinite"/>
</rect>
<rect x="140" y="35" width="25" height="24" rx="0 12 12 0" fill="#2563eb" opacity="0.85">
  <animate attributeName="y" values="35;28;35" dur="2.5s" repeatCount="indefinite"/>
</rect>
<!-- Syringe (GLP-1) -->
<rect x="200" y="38" width="55" height="10" rx="3" fill="#e8913a" opacity="0.8">
  <animate attributeName="y" values="38;33;38" dur="3.5s" repeatCount="indefinite"/>
</rect>
<rect x="255" y="41" width="12" height="4" rx="1" fill="#e8913a">
  <animate attributeName="y" values="41;36;41" dur="3.5s" repeatCount="indefinite"/>
</rect>
<text x="140" y="85" text-anchor="middle" font-size="9" fill="#64748b">Oral &amp; Injectable Medications</text>
</svg>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F4CB;</span> Overview of Pharmacotherapy in Type 2 Diabetes</h2>
<p>When lifestyle modifications alone are insufficient to achieve glycemic targets, pharmacological therapy is initiated. The choice of medication depends on multiple patient-specific factors: HbA1c level, presence of cardiovascular disease (CVD) or chronic kidney disease (CKD), risk of hypoglycemia, weight considerations, cost, and patient preference.</p>
<p>The ADA/EASD consensus algorithm recommends:</p>
<ul>
<li><strong>First-line:</strong> Metformin (unless contraindicated) alongside lifestyle modification.</li>
<li><strong>For patients with established CVD or high CV risk:</strong> Add a GLP-1 RA or SGLT2 inhibitor with proven cardiovascular benefit, regardless of HbA1c.</li>
<li><strong>For patients with heart failure:</strong> Prefer an SGLT2 inhibitor.</li>
<li><strong>For patients with CKD:</strong> Prefer an SGLT2 inhibitor (if eGFR adequate) and/or a GLP-1 RA.</li>
<li><strong>For patients where weight loss is a priority:</strong> Prefer GLP-1 RA or dual GIP/GLP-1 RA (tirzepatide) or SGLT2 inhibitor.</li>
<li><strong>For patients where cost is a major concern:</strong> Metformin, sulfonylureas, and thiazolidinediones are the most affordable.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F4CA;</span> Drug Classes Summary Table</h2>

<div class="info-cards">
<div class="info-card"><span class="ic-icon">&#x1F48A;</span><div class="ic-title">Metformin</div><div class="ic-text">First-line &bull; Low hypo risk &bull; HbA1c -1.0-1.5%</div></div>
<div class="info-card"><span class="ic-icon">&#x1FAB7;</span><div class="ic-title">SGLT2 Inhibitors</div><div class="ic-text">Heart &amp; kidney protection &bull; Weight loss &bull; Low hypo risk</div></div>
<div class="info-card"><span class="ic-icon">&#x1F489;</span><div class="ic-title">GLP-1 Agonists</div><div class="ic-text">Strongest weight loss &bull; CV benefit &bull; HbA1c -1.0-1.8%</div></div>
<div class="info-card"><span class="ic-icon">&#x2B50;</span><div class="ic-title">Tirzepatide</div><div class="ic-text">Dual GIP/GLP-1 &bull; Most potent &bull; HbA1c -1.5-2.4%</div></div>
</div>
<div class="table-wrap">
<table>
<thead>
<tr><th>Drug Class</th><th>Examples</th><th>HbA1c Reduction</th><th>Hypoglycemia Risk</th><th>Weight Effect</th><th>Key Benefit</th></tr>
</thead>
<tbody>
<tr><td>Biguanides</td><td>Metformin</td><td>1.0–1.5%</td><td>Low</td><td>Neutral / slight loss</td><td>First-line; low cost; long safety record</td></tr>
<tr><td>Sulfonylureas</td><td>Glimepiride, Gliclazide, Glipizide</td><td>1.0–1.5%</td><td><strong>Moderate–High</strong></td><td>Weight gain</td><td>Low cost; rapid efficacy</td></tr>
<tr><td>DPP-4 Inhibitors</td><td>Sitagliptin, Vildagliptin, Linagliptin, Saxagliptin</td><td>0.5–0.8%</td><td>Low</td><td>Neutral</td><td>Well-tolerated; weight neutral</td></tr>
<tr><td>SGLT2 Inhibitors</td><td>Empagliflozin, Dapagliflozin, Canagliflozin</td><td>0.5–1.0%</td><td>Low</td><td>Weight loss (2–3 kg)</td><td>CV and kidney protection; BP reduction</td></tr>
<tr><td>GLP-1 Receptor Agonists</td><td>Semaglutide, Liraglutide, Dulaglutide, Exenatide</td><td>1.0–1.8%</td><td>Low</td><td>Significant weight loss</td><td>CV benefit; weight loss; strong HbA1c reduction</td></tr>
<tr><td>Dual GIP/GLP-1 RA</td><td>Tirzepatide</td><td>1.5–2.4%</td><td>Low</td><td>Major weight loss</td><td>Most potent HbA1c and weight reduction</td></tr>
<tr><td>Thiazolidinediones</td><td>Pioglitazone</td><td>1.0–1.5%</td><td>Low</td><td>Weight gain</td><td>Improves insulin sensitivity; durable</td></tr>
<tr><td>Alpha-Glucosidase Inhibitors</td><td>Acarbose, Voglibose, Miglitol</td><td>0.5–0.8%</td><td>Low</td><td>Neutral</td><td>Reduces post-meal spikes</td></tr>
<tr><td>Meglitinides</td><td>Repaglinide, Nateglinide</td><td>0.5–1.0%</td><td>Moderate</td><td>Weight gain</td><td>Short-acting; flexible meal timing</td></tr>
</tbody>
</table>
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F48A;</span> Metformin (Biguanide)</h2>
<p>Metformin has been the first-line medication for T2D for over 60 years and remains the most widely prescribed diabetes drug worldwide.</p>

<h3>Mechanism of Action</h3>
<ul>
<li>Reduces hepatic glucose production (primary mechanism) — suppresses gluconeogenesis in the liver.</li>
<li>Improves peripheral insulin sensitivity — enhances glucose uptake in muscle tissue.</li>
<li>Modestly reduces intestinal glucose absorption.</li>
<li>Activates AMP-activated protein kinase (AMPK), a key energy-sensing enzyme.</li>
</ul>

<h3>Dosing</h3>
<ul>
<li><strong>Starting dose:</strong> 500 mg once or twice daily with meals.</li>
<li><strong>Titration:</strong> Increase by 500 mg every 1–2 weeks as tolerated.</li>
<li><strong>Maximum dose:</strong> 2,000–2,550 mg/day (divided into 2–3 doses).</li>
<li><strong>Extended-release (XR):</strong> 500–2,000 mg once daily with evening meal — better GI tolerance.</li>
</ul>

<h3>Side Effects</h3>
<ul>
<li><strong>Gastrointestinal:</strong> Nausea, diarrhea, bloating, metallic taste — most common reason for discontinuation. Usually improves over 2–4 weeks. Mitigated by starting low, titrating slowly, and taking with food. XR formulation has fewer GI side effects.</li>
<li><strong>Vitamin B12 deficiency:</strong> Long-term use reduces B12 absorption by 10–30%. Monitor B12 levels periodically, especially in patients with anemia or neuropathy.</li>
<li><strong>Lactic acidosis:</strong> Extremely rare (estimated 3–10 cases per 100,000 patient-years). Risk factors include severe renal impairment, hepatic failure, sepsis, and excessive alcohol.</li>
</ul>

<h3>Contraindications</h3>
<ul>
<li>eGFR &lt; 30 mL/min/1.73m&sup2; (contraindicated). Dose reduction at eGFR 30–45. Can generally be used safely at eGFR &ge; 45.</li>
<li>Active or worsening heart failure with risk of hypoperfusion.</li>
<li>Temporarily hold before iodinated contrast procedures and for 48 hours after.</li>
</ul>

<div class="tip">
<strong>Why Metformin Is First-Line:</strong> Effective HbA1c reduction, very low hypoglycemia risk, weight neutrality, extremely low cost, possible cardiovascular benefits (UKPDS data), and a 60+ year safety track record make metformin the standard starting medication for T2D.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x26A1;</span> Sulfonylureas</h2>
<p>Sulfonylureas are among the oldest oral diabetes medications, still widely used due to their potency and low cost.</p>

<h3>Mechanism</h3>
<p>Bind to the SUR1 receptor on pancreatic beta cells, closing ATP-sensitive potassium channels, causing depolarization and insulin secretion — independent of blood glucose levels (which is why they can cause hypoglycemia).</p>

<h3>Common Agents</h3>
<ul>
<li><strong>Glimepiride:</strong> 1–4 mg once daily. Preferred newer-generation SU.</li>
<li><strong>Gliclazide (modified release):</strong> 30–120 mg once daily. Lower hypoglycemia risk than other SUs. Preferred in many guidelines.</li>
<li><strong>Glipizide:</strong> 2.5–20 mg daily (immediate or extended release).</li>
<li><strong>Glyburide/Glibenclamide:</strong> 1.25–20 mg daily. Highest hypoglycemia risk — generally avoided in elderly and CKD patients.</li>
</ul>

<h3>Side Effects</h3>
<ul>
<li><strong>Hypoglycemia:</strong> The most significant risk. More common with glyburide, long-acting agents, missed meals, excessive exercise, or renal impairment.</li>
<li><strong>Weight gain:</strong> Average 2–4 kg, due to insulin-stimulating effect and corrective eating for hypoglycemia.</li>
<li><strong>Secondary failure:</strong> Over time, effectiveness diminishes as beta cells decline.</li>
</ul>

<div class="warning">
<strong>Caution:</strong> Sulfonylureas should be used cautiously in the elderly and in patients with renal impairment. Gliclazide and glipizide are preferred in these populations due to shorter duration of action and lower hypoglycemia risk. Glyburide should generally be avoided.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F9EC;</span> DPP-4 Inhibitors (Gliptins)</h2>
<p>DPP-4 inhibitors enhance the body's incretin system by preventing the breakdown of GLP-1 and GIP hormones.</p>

<h3>Mechanism</h3>
<p>Inhibit the enzyme dipeptidyl peptidase-4 (DPP-4), which normally degrades the incretin hormones GLP-1 and GIP within minutes. By prolonging their activity, GLP-1 stimulates glucose-dependent insulin secretion and suppresses glucagon.</p>

<h3>Key Agents</h3>
<ul>
<li><strong>Sitagliptin (Januvia):</strong> 100 mg once daily. Dose reduction in CKD.</li>
<li><strong>Vildagliptin (Galvus):</strong> 50 mg twice daily.</li>
<li><strong>Saxagliptin (Onglyza):</strong> 5 mg once daily. Caution: associated with increased heart failure hospitalization (SAVOR-TIMI 53 trial).</li>
<li><strong>Linagliptin (Tradjenta):</strong> 5 mg once daily. No dose adjustment needed in renal impairment (hepatic elimination). Preferred in CKD.</li>
<li><strong>Alogliptin (Nesina):</strong> 25 mg once daily.</li>
</ul>

<h3>Advantages</h3>
<ul>
<li>Weight neutral</li>
<li>Very low hypoglycemia risk (glucose-dependent mechanism)</li>
<li>Well-tolerated; oral once-daily dosing</li>
<li>Can be used in mild to moderate CKD (with dose adjustment except linagliptin)</li>
</ul>

<h3>Side Effects</h3>
<ul>
<li>Nasopharyngitis, upper respiratory infections, headache</li>
<li>Rare reports of pancreatitis (monitor for severe abdominal pain)</li>
<li>Joint pain (arthralgia) — rare</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1FAB7;</span> SGLT2 Inhibitors (Gliflozins)</h2>
<p>SGLT2 inhibitors represent one of the most important advances in diabetes treatment due to their cardiovascular and kidney-protective effects.</p>

<h3>Mechanism</h3>
<p>Block the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubule of the kidney, preventing glucose reabsorption. This causes approximately 60–80 grams of glucose to be excreted in the urine daily (glycosuria), lowering blood glucose through an insulin-independent mechanism.</p>

<h3>Key Agents</h3>
<ul>
<li><strong>Empagliflozin (Jardiance):</strong> 10–25 mg once daily. EMPA-REG OUTCOME: 38% reduction in CV death.</li>
<li><strong>Dapagliflozin (Farxiga/Forxiga):</strong> 5–10 mg once daily. DAPA-HF and DAPA-CKD trials showed benefit even in patients without diabetes.</li>
<li><strong>Canagliflozin (Invokana):</strong> 100–300 mg once daily. CANVAS and CREDENCE trials showed CV and kidney benefits.</li>
<li><strong>Ertugliflozin (Steglatro):</strong> 5–15 mg once daily.</li>
</ul>

<h3>Benefits Beyond Glucose Control</h3>
<ul>
<li><strong>Cardiovascular protection:</strong> Reduces major adverse cardiovascular events (MACE), cardiovascular death, and heart failure hospitalization.</li>
<li><strong>Kidney protection:</strong> Slows progression of diabetic kidney disease, reduces albuminuria, delays need for dialysis.</li>
<li><strong>Blood pressure reduction:</strong> Lowers systolic BP by 3–5 mmHg (osmotic diuresis).</li>
<li><strong>Weight loss:</strong> Average 2–3 kg sustained weight loss.</li>
</ul>

<h3>Side Effects</h3>
<ul>
<li><strong>Genital mycotic infections:</strong> Increased risk of yeast infections (vulvovaginal candidiasis, balanitis) due to glycosuria. Occurs in 5–10% of users. Treatable with antifungals; improved hygiene helps prevent recurrence.</li>
<li><strong>Urinary tract infections:</strong> Modestly increased risk.</li>
<li><strong>Volume depletion:</strong> Polyuria, dehydration, orthostatic hypotension — particularly in elderly patients or those on diuretics.</li>
<li><strong>Diabetic ketoacidosis (euglycemic DKA):</strong> Rare but serious. Can occur with near-normal glucose levels, making diagnosis difficult. Higher risk in T1D (off-label use), surgery, illness, or reduced food intake. Hold SGLT2i before surgery and during acute illness.</li>
<li><strong>Fournier's gangrene:</strong> Extremely rare necrotizing fasciitis of the perineum. Seek immediate care for genital pain, tenderness, redness, or swelling with fever.</li>
</ul>

<div class="warning">
<strong>Important:</strong> SGLT2 inhibitors should be held 3–4 days before scheduled surgery and during serious illness to reduce the risk of euglycemic DKA. They should not be started if eGFR is too low for glucose-lowering effect (thresholds vary by agent, generally &lt; 20–30 mL/min), though they may be continued for kidney/heart protection at lower eGFR levels per updated guidelines.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F489;</span> GLP-1 Receptor Agonists</h2>
<p>GLP-1 RAs are injectable (and now oral) medications that mimic the incretin hormone GLP-1, providing potent glucose lowering and significant weight loss.</p>

<h3>Mechanism</h3>
<ul>
<li>Stimulate glucose-dependent insulin secretion (low hypoglycemia risk).</li>
<li>Suppress glucagon secretion.</li>
<li>Slow gastric emptying — reduces post-meal glucose spikes.</li>
<li>Act on brain appetite centers — promote satiety and reduce food intake.</li>
</ul>

<h3>Key Agents</h3>
<div class="table-wrap">
<table>
<thead>
<tr><th>Agent</th><th>Route</th><th>Frequency</th><th>HbA1c Reduction</th><th>Weight Loss</th><th>CV Outcome Trial</th></tr>
</thead>
<tbody>
<tr><td><strong>Semaglutide (Ozempic)</strong></td><td>SC injection</td><td>Weekly</td><td>1.5–1.8%</td><td>4–6 kg</td><td>SUSTAIN-6: CV benefit</td></tr>
<tr><td><strong>Oral semaglutide (Rybelsus)</strong></td><td>Oral tablet</td><td>Daily</td><td>1.0–1.4%</td><td>3–4 kg</td><td>PIONEER-6: non-inferior</td></tr>
<tr><td><strong>Liraglutide (Victoza)</strong></td><td>SC injection</td><td>Daily</td><td>1.0–1.5%</td><td>2–3 kg</td><td>LEADER: CV benefit</td></tr>
<tr><td><strong>Dulaglutide (Trulicity)</strong></td><td>SC injection</td><td>Weekly</td><td>1.0–1.5%</td><td>2–3 kg</td><td>REWIND: CV benefit</td></tr>
<tr><td><strong>Exenatide ER (Bydureon)</strong></td><td>SC injection</td><td>Weekly</td><td>1.0–1.5%</td><td>2–3 kg</td><td>EXSCEL: non-inferior</td></tr>
<tr><td><strong>Tirzepatide (Mounjaro)</strong></td><td>SC injection</td><td>Weekly</td><td>1.5–2.4%</td><td>5–12 kg</td><td>SURPASS trials; CV trial (SURPASS-CVOT) ongoing</td></tr>
</tbody>
</table>
</div>

<h3>Side Effects</h3>
<ul>
<li><strong>Gastrointestinal:</strong> Nausea, vomiting, diarrhea — most common side effects. Usually mild to moderate and diminish over weeks. Start at the lowest dose and titrate slowly.</li>
<li><strong>Injection site reactions:</strong> Mild redness or itching at injection site.</li>
<li><strong>Pancreatitis:</strong> Rare. Discontinue if suspected (severe, persistent abdominal pain).</li>
<li><strong>Gallbladder disease:</strong> Slightly increased risk of cholelithiasis with rapid weight loss.</li>
<li><strong>Thyroid C-cell tumors:</strong> Observed in rodent studies at high doses. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. No confirmed cases in humans to date.</li>
</ul>

<div class="tip">
<strong>Oral Semaglutide (Rybelsus) — Dosing Instructions:</strong> Must be taken on an empty stomach with no more than 4 ounces (120 mL) of plain water, at least 30 minutes before any food, other beverages, or other oral medications. This is necessary for absorption. Start at 3 mg daily for 30 days, then increase to 7 mg, then optionally to 14 mg.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F6E1;&#xFE0F;</span> Thiazolidinediones (TZDs)</h2>

<h3>Mechanism</h3>
<p>Activate the nuclear receptor PPAR-gamma, improving insulin sensitivity in adipose tissue, muscle, and liver. They promote adipocyte differentiation and redistribute fat from visceral to subcutaneous depots.</p>

<h3>Key Agent</h3>
<ul>
<li><strong>Pioglitazone (Actos):</strong> 15–45 mg once daily. The only TZD in common use (rosiglitazone was largely withdrawn due to CV safety concerns).</li>
</ul>

<h3>Benefits</h3>
<ul>
<li>Durable glucose lowering (preserves beta-cell function longer than SUs)</li>
<li>Improves insulin sensitivity</li>
<li>Reduces liver fat (benefit in NAFLD/NASH)</li>
<li>PROactive trial showed trend toward CV benefit</li>
<li>Low hypoglycemia risk</li>
</ul>

<h3>Side Effects</h3>
<ul>
<li><strong>Weight gain:</strong> 2–5 kg, partly due to fluid retention and partly due to increased subcutaneous fat.</li>
<li><strong>Fluid retention and edema:</strong> Can worsen heart failure — contraindicated in NYHA Class III–IV heart failure.</li>
<li><strong>Bone fractures:</strong> Increased risk, particularly in postmenopausal individuals. Avoid in patients with osteoporosis.</li>
<li><strong>Bladder cancer:</strong> Possible small increased risk with prolonged use (controversial; under ongoing surveillance).</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F35E;</span> Alpha-Glucosidase Inhibitors</h2>

<h3>Mechanism</h3>
<p>Competitively inhibit alpha-glucosidase enzymes in the small intestinal brush border, delaying the digestion and absorption of complex carbohydrates. This blunts the post-meal glucose spike.</p>

<h3>Key Agents</h3>
<ul>
<li><strong>Acarbose:</strong> 25–100 mg three times daily, taken with the first bite of each main meal.</li>
<li><strong>Voglibose:</strong> 0.2–0.3 mg three times daily.</li>
<li><strong>Miglitol:</strong> 25–100 mg three times daily.</li>
</ul>

<h3>Side Effects</h3>
<ul>
<li><strong>Gastrointestinal:</strong> Flatulence, bloating, diarrhea — caused by fermentation of undigested carbohydrates in the colon. Very common and often limits tolerability. Starting at a low dose and titrating slowly can help.</li>
<li>Must treat hypoglycemia with pure glucose (dextrose tablets), not sucrose, because acarbose blocks sucrose digestion.</li>
</ul>

<div class="note">
<strong>When Are Alpha-Glucosidase Inhibitors Useful?</strong> They are most helpful in patients with primarily post-prandial hyperglycemia and in populations with high-carbohydrate diets (e.g., rice-based diets in Asian countries, where these agents are widely used). The STOP-NIDDM trial also showed benefit in prediabetes prevention.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F9ED;</span> Choosing the Right Medication — Decision Framework</h2>
<div class="table-wrap">
<table>
<thead>
<tr><th>Patient Profile</th><th>Preferred Agent(s)</th></tr>
</thead>
<tbody>
<tr><td>First-line, no comorbidities</td><td>Metformin</td></tr>
<tr><td>Established CVD or high CV risk</td><td>GLP-1 RA (semaglutide, liraglutide, dulaglutide) or SGLT2i (empagliflozin, dapagliflozin)</td></tr>
<tr><td>Heart failure</td><td>SGLT2i (empagliflozin, dapagliflozin)</td></tr>
<tr><td>CKD (diabetic kidney disease)</td><td>SGLT2i + consider finerenone; GLP-1 RA</td></tr>
<tr><td>Obesity / need for weight loss</td><td>GLP-1 RA or tirzepatide; SGLT2i as second choice</td></tr>
<tr><td>Hypoglycemia is a major concern</td><td>Avoid SUs; prefer DPP-4i, SGLT2i, GLP-1 RA, TZDs</td></tr>
<tr><td>Cost is the primary constraint</td><td>Metformin, SUs (gliclazide/glimepiride), pioglitazone</td></tr>
<tr><td>Post-prandial glucose is the main issue</td><td>Acarbose, GLP-1 RA, DPP-4i, meglitinides</td></tr>
</tbody>
</table>
</div>
</div>

<div class="page-nav">
<a class="prev" href="blood-sugar-monitoring.html">Blood Sugar Monitoring</a>
<a class="next" href="insulin-guide.html">Insulin Guide</a>
</div>
</div>
<div class="disclaimer">This content is for educational purposes only and does not replace professional medical advice. The creators of SugarWise are not medical professionals. Do not start, stop, or change any medication without consulting your doctor. In case of emergency, call 112 (India) or your local emergency number. <a href="terms-of-use.html">Read full Terms of Use &amp; Medical Disclaimer</a></div>
<div class="privacy-notice">SugarWise does not use cookies, collect personal data, or track users.</div>
<div class="footer"><span class="ai-badge">AI-Assisted Content</span><br>SugarWise &bull; Comprehensive Diabetes Management Companion &bull; <a href="terms-of-use.html">Terms of Use</a> &bull; Last updated: January 2026</div>
<button class="scroll-top" id="scrollTop" title="Back to top">&uarr;</button>
<script>
var sb=document.getElementById('scrollTop');window.addEventListener('scroll',function(){sb.classList.toggle('visible',window.scrollY>400)});sb.addEventListener('click',function(){window.scrollTo({top:0,behavior:'smooth'})});
document.querySelectorAll('.accordion-header').forEach(function(h){h.addEventListener('click',function(){this.parentElement.classList.toggle('open')})});
</script>
</body></html>